Medicure Reports Financial Results for Quarter and Year Ended December 31, 2020
With the acquisition of the Marley Drug business in December of 2020, including direct to patient marketing, and improved insurance coverage experienced during 2020, the Company has seen some growth in interest in ZYPITAMAG during 2020.
- With the acquisition of the Marley Drug business in December of 2020, including direct to patient marketing, and improved insurance coverage experienced during 2020, the Company has seen some growth in interest in ZYPITAMAG during 2020.
- Marley provides excellent customer service, cost competitive medications, expedited direct to patient delivery, and is licensed in 49 states, Washington D.C. and Puerto Rico.
- Its advanced operating systems include automated pill dispensing, an extended supply generic drug program, and an effective customer communication system.
- The Company also earned $95,000 of revenue from ReDSTM during the year ended December 31, 2020 compared to $618,000 for the year ended December 31, 2019.\nAdjusted EBITDA for the three months ended December 31, 2020 was negative $2.9 million compared to negative $1.9 million for the three months ended December 31, 2019.